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OBJECTIVE — To compare the sensitivity and speciﬁcity of luciferase immunoprecipitation
(LIPS) with radioimmunoprecipitation (RIP) for the measurement of autoantibodies to the type
1 diabetes autoantigens glutamic acid decarboxylase 65 (GAD65) and insulinoma-associated
protein (IA)-2.
RESEARCH DESIGN AND METHODS — Sera from 49 type 1 diabetic patients and
100 nondiabetic control subjects from Diabetes Antibody Standardization Program 2007 were
used to screen for autoantibodies to GAD65. An additional 200 type 1 diabetic patients and 200
nondiabetic control subjects were used to validate the GAD65 results and screen for autoantibod-
ies to IA-2.
RESULTS — LIPSshowedequalsensitivityandspeciﬁcitytoRIPfordetectingautoantibodies
to GAD65 and IA-2. Receiver-operating characteristic analysis revealed that the detection of
autoantibodies to GAD65 and IA-2 by LIPS and RIP were not statistically different.
CONCLUSIONS — The LIPS assay does not require the use of radioisotopes or in vitro
transcription/translation and is a practical alternative at the clinical level for the RIP assay.
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A
utoantibodies to glutamic acid de-
carboxylase 65 (GAD65), insuli-
noma-associated protein (IA)-2,
and IA-2 are major diagnostic and pre-
dictive markers in type 1 diabetes (1,2).
Autoantibodies to these proteins, which
appear years before the development of
clinical disease and in combination with
certainHLAhaplotypes,arebeingusedto
enter subjects into therapeutic interven-
tion trials (3). The radioimmunoprecipi-
tation (RIP) assay has been used
extensively to detect these autoantibod-
ies. Recently, we showed that luciferase
immunoprecipitation (LIPS) displayed
equal sensitivity and speciﬁcity to RIP for
detecting IA-2 autoantibodies (4). The
present experiments were initiated to see
whether LIPS could be used to measure
autoantibodies to GAD65 and IA-2 with
asensitivityandspeciﬁcityequaltothatof
RIP.
RESEARCH DESIGN AND
METHODS— FortheLIPSassay,full-
lengthGAD65ortheintracellularportion
of IA-2 (aa 662–1,033) (5) was cloned
into the pREN2 vector downstreamof the
Renilla luciferase reporter, and extracts
werepreparedfromtransfectedCos1cells
as described (4–6). For the RIP assay,
GAD65 and IA-2 were cloned into
pTNT and pGBKT7 vectors, respectively,
and the [
35S] methionine–labeled pro-
teins were produced by in vitro transcrip-
tion/translation (7). Autoantibodies to
GAD65 and IA-2 were detected by liq-
uid-phase immunoprecipitation using
1.0  10
7 light units (LU) of cell extracts
in LIPS and 40,000 counts per minute
(cpm) of radiolabeled protein for RIP.
Sera from 100 control and 49 type 1
diabetic patients were obtained from the
2007 Diabetes Antibody Standardization
Program (DASP) (8) and used to measure
autoantibodiestoGAD65.Inthe2007se-
rum exchange, sensitivity and speciﬁcity
forautoantibodiestoGAD65were82and
96%, respectively. Control subjects from
the DASP included some samples with
high levels of islet autoantibodies, pre-
sumably because they were from subjects
whowereathighriskofdevelopingtype1
diabetes. Neither the DASP patients with
type 1 diabetes nor the control subjects
are representative of the type 1 diabetic
population or the general public. Addi-
tional sera from 200 age-matched nondi-
abetic control subjects and 200 type 1
diabetic subjects (Malmo ¨ Diabetes Study)
(9) were used to validate the GAD65
ﬁndings and measure autoantibodies to
IA-2.Aserumwaspositiveiftheprecip-
itated cpm or LU exceeded the mean  3
SD of the control subjects. MedCalc Soft-
ware (Mariakerke, Belgium) was used for
statistical analyses. Signal-to-noise ratios
of autoantibodies for RIP and LIPS in the
type 1 diabetic samples were determined
as described (10).
RESULTS— Anti-GAD65 autoanti-
bodies determined by LIPS showed that
only3of100nondiabeticcontrolsubjects
were positive (Fig. 1A). In contrast,
77.6%(38of49)oftheserafrompatients
withtype1diabeteswerepositivebyLIPS
with a speciﬁcity of 97%. In RIP, 5 of 100
nondiabetic control subjects were auto-
antibody positive, whereas 77.6% (38 of
49) of the sera from subjects with type 1
diabetes were autoantibody positive (Fig.
1B), with a speciﬁcity of 95%. The coefﬁ-
cient of variation (CV) for duplicate sam-
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(supplemental Fig. 1A [available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1938/DC1). Comparison of the
assays revealed a high coefﬁcient of de-
termination with an R
2 of 0.778 (sup-
plemental Fig. 1C). Receiver-operating
characteristic (ROC) analysis showed
that the area under the curves for autoan-
tibodies to GAD65 by LIPS and RIP were
notstatisticallydifferent(P0.592)(Fig.
1E). Validation studies for GAD65 auto-
Figure1—GAD65autoantibodiesasdeterminedbyLIPS(A)andRIP(B)andIA-2autoantibodiesasdeterminedbyLIPS(C)andRIP(D).Dotted
lines represent 3 SDs above the mean of the nondiabetic control sera. E: ROC analysis showing the area under the curve for GAD autoantibodies by
LIPS (0.929 [95% CI 0.875–0.964]) and by RIP (0.941 [0.891–0.973]). There was no statistical difference (P  0.592). F: ROC analysis showing
the area under the curve for IA-2 autoantibodies by LIPS (0.844 [0.804– 0.879]) and by RIP (0.807 [0.763–0.849]). There was no statistical
difference (P  0.062).
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revealed 53.5% positivity by LIPS and
49.3%positivitybyRIP(datanotshown).
LIPS proﬁling of IA-2 autoantibod-
ies revealed that none of the 200 nondia-
beticcontrolserawerepositive(Fig.1C).In
contrast, 62.5% (125 of 200) of type 1 dia-
betic subjects were autoantibody positive
with a speciﬁcity of 100%. In RIP, 3 of 200
nondiabetic control sera were positive,
whereas 51.0% (102 of 200) of the sera
from subjects with type 1 diabetes were au-
toantibody positive (Fig. 1D) with a 97.5%
speciﬁcity. The CV for duplicate samples
was 10.9% for LIPS and 6.8% for RIP (sup-
plemental Fig. 1B). Comparison of the as-
says revealed a high coefﬁcient of
determination,withanR
2of0.904(supple-
mental Fig. 1D). ROC analysis showed that
theareaunderthecurvesforautoantibodies
to IA-2 by LIPS and RIP were not statisti-
cally different (P  0.062) (Fig. 1F). How-
ever, the signal-to-noise ratio for detecting
autoantibodies to GAD65 and IA-2 was
higher as determined by LIPS than by RIP
(Fig. 1A–Dand supplemental Fig. 1Eand F).
CONCLUSIONS — In nondiabetic
subjects, the presence of autoantibodies
to more than one of the major diabetes-
associated autoantigens is a better predic-
torofthedevelopmentofclinicaldiabetes
than the presence of any single autoanti-
body (3). Initially, autoantibodies di-
rected against islet cells (ICAs) were
detected by immunoﬂuorescence. In re-
cent years, the ICA technique has been
replaced by the quantitative RIP assay. In
the present report on autoantibodies to
GAD65 and IA-2 and in our recent re-
port on autoantibodies to IA-2 (4), we
showedthattheliquid-phaseLIPSassayis
equal in sensitivity and speciﬁcity to the
liquid-phase RIP assay, in that the two
assays have a high correlation coefﬁcient
and that, by ROC analysis, the areas
under the curves are not statistically
different.
Although further documentation is
needed, our current study shows that the
sensitivity for detecting autoantibodies to
IA-2 by LIPS is not only equal to that of
RIP but may be slightly higher (62.5 vs.
51.0%). Also, the signal-to-noise ratio is
higher for LIPS compared with RIP, but
the clinical signiﬁcance of the very high
autoantibody-positive sera detected in
LIPS is not known at this time. Moreover,
we have no concrete evidence that the
LIPS assay is more reliable or sensitive
than the RIP assay for discriminating bor-
derline autoantibody-positive and -nega-
tive sera. It is the failure to reproducibly
distinguishbetweenpositiveandnegative
signals at the borderline that is responsi-
ble for much of the variation in routine
autoantibody assays.
Although LIPS and RIP appear to be
equal in sensitivity and speciﬁcity, LIPS
has the advantage for a clinical laboratory
of not requiring the use of radioisotopes,
avoids the time and expense of in vitro
transcription/translation, and offers the
potential of detecting mammalian cell
posttranslational modiﬁcations, which
would not be found in a bacterial expres-
sion system or by in vitro transcription/
translation. Use of a mixture of Renilla
luciferase–tagged antigen with ﬁreﬂy lu-
ciferase–tagged antigen may also allow
detection of autoantibodies to two differ-
ent autoantigens at the same time.
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